Cargando…
Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues
Since the discovery of spliceosome mutations in myeloid malignancies, abnormal pre-mRNA splicing, which has been well studied in various cancers, has attracted novel interest in hematology. However, despite the common occurrence of spliceosome mutations in myelo-proliferative neoplasms (MPN), not mu...
Autores principales: | Hautin, Marie, Mornet, Clélia, Chauveau, Aurélie, Bernard, Delphine G., Corcos, Laurent, Lippert, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464941/ https://www.ncbi.nlm.nih.gov/pubmed/32784800 http://dx.doi.org/10.3390/cancers12082216 |
Ejemplares similares
-
Paving the way to improve therapy for Myeloproliferative Neoplasms
por: Bywater, Megan, et al.
Publicado: (2022) -
Paving the future: finding suitable ISMB venues
por: Rost, Burkhard, et al.
Publicado: (2012) -
Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
por: Ianotto, Jean-Christophe, et al.
Publicado: (2018) -
Novel therapeutics in myeloproliferative neoplasms
por: Venugopal, Sangeetha, et al.
Publicado: (2020) -
Human Cancer-Associated Mutations of SF3B1 Lead to a Splicing Modification of Its Own RNA
por: Bergot, Tiffany, et al.
Publicado: (2020)